MedTrace Logo

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

NCT02459938 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-08-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether glucagon administered by microneedle patch is comparable to glucagon administered by injection pen in the treatment of insulin-induced hypoglycemia.

Conditions

Interventions

DRUG

Glucagon (ZP-Glucagon)

chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes

DRUG

Glucagon (GlucaGen)

recombinant glucagon administered via subcutaneous injection

Sponsors & Collaborators

  • Zosano Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Neale Cohen, MD · Baker ID Heart and Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-08-31
Completion
2015-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459938 on ClinicalTrials.gov